MedTrace Logo

YF476 and Type II Gastric Carcinoids

NCT02454075 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-01-29

Study results available
· View outcomes & findings →

Summary

This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.

Conditions

  • Zollinger-Ellison Syndrome

Interventions

DRUG

YF476

Gastrin receptor antagonist

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Trio Medicines Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-11
Primary Completion
2012-06-22
Completion
2012-06-22

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02454075 on ClinicalTrials.gov